BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsCompany update

Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 CHICAGO --(BUSINESS WIRE)--Feb. 26, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing

Related news

XERSXeris Pharmaceuticals2026-06-11 20:39 EST

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

View all latest news

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

XERSXeris Pharmaceuticals2026-06-30 11:00 EST

Xeris Announces Updates to Its Board of Directors

Stock data

Close
8.70 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States